Markets · Breaking
Sellas shares climb higher following positive leukemia drug trial results
Originally reported by LiveMint Markets as: After 156% surge in a day, this American firm stock rises another 5%. What's driving the biotech share rally?
18 Nov 2026, 9:41 pm IST · Xecute.finance News DeskArchive edition
The crisp read
Sellas stock advanced another five percent following a previous single-day surge of one hundred fifty-six percent. A late-stage trial of its drug GPS demonstrated survival benefits for acute myeloid leukemia patients without new safety concerns, prompting plans for a two thousand twenty-seven application.
Deep dive – the full story
American biotechnology firm Sellas experienced a five percent share price increase following an earlier one hundred fifty-six percent single-day rally. The upward movement was driven by a Phase three clinical trial of its agent GPS, which showed significant survival benefits for individuals suffering from acute myeloid leukemia alongside an absence of new safety issues. The company intends to consult with the regulatory authority regarding an accelerated filing pathway and targets a formal submission in the year two thousand twenty-seven.
Clinical trials are rigorous scientific evaluations conducted in multiple phases to test the efficacy and safety of new medical treatments before commercial release. Phase three trials represent the final stage of evaluation on large patient cohorts prior to seeking regulatory authorization. Biotechnology share valuations frequently react with extreme volatility to clinical trial data releases because commercial viability depends entirely on successful regulatory approvals. Life sciences investors and equity analysts must closely track regulatory interaction milestones and trial data disclosures rather than relying solely on short-term price momentum.
Advertisement
Portfolio managers holding high-beta biotechnology stocks should maintain strict risk management protocols to handle sudden valuation swings. Bottom line: Clinical trial outcomes dictate immediate stock valuations in the biotechnology sector.
Source: livemint.com
This is news/educational content, not investment advice. Xecute.finance is not SEBI-registered. Consult a qualified professional before acting.
Advertisement
More from the Xecute news desk
- Reliance Brands FY26 revenue up 3.8% to Rs 3,390.9 crore; loss narrows to Rs 137 crore
- Share Market News: Nifty 50 Outlook & Prediction
- Top 3 stocks to buy: Swiggy, Tata Chemicals, Amber Enterprises by Ganesh Dongre of Anand Rathi | Targets, stop-loss
- Broader markets underperform; Kaynes Tech, Inox Wind, CreditAccess, KEC International down 10-15%
Advertisement
Reading the archive edition.
This story has retired from the live feed - the full text stays here permanently. The live app adds the newest desk, Ask Xecute, deadline trackers and the daily quiz.
Open this story in the Xecute app →